A detailed history of Royal Bank Of Canada transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 7,692 shares of PSTX stock, worth $21,999. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,692
Previous 7,684 0.1%
Holding current value
$21,999
Previous $22,000 4.55%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.7 - $4.04 $21 - $32
8 Added 0.1%
7,692 $21,000
Q2 2024

Aug 14, 2024

BUY
$2.0 - $3.46 $9,730 - $16,832
4,865 Added 172.58%
7,684 $22,000
Q1 2024

Nov 05, 2024

SELL
$2.76 - $4.13 $13,427 - $20,092
-4,865 Reduced 63.31%
2,819 $8,000
Q1 2024

May 15, 2024

SELL
$2.76 - $4.13 $56,720 - $84,875
-20,551 Reduced 87.94%
2,819 $8,000
Q4 2023

Feb 14, 2024

BUY
$1.83 - $3.51 $19,513 - $37,427
10,663 Added 83.91%
23,370 $78,000
Q3 2023

Nov 14, 2023

BUY
$1.62 - $2.79 $7,129 - $12,278
4,401 Added 52.99%
12,707 $30,000
Q2 2023

Aug 14, 2023

BUY
$1.66 - $3.4 $9,812 - $20,097
5,911 Added 246.81%
8,306 $14,000
Q1 2023

May 15, 2023

BUY
$3.08 - $8.73 $2,189 - $6,207
711 Added 42.22%
2,395 $7,000
Q4 2022

Feb 14, 2023

SELL
$3.33 - $6.38 $13,313 - $25,507
-3,998 Reduced 70.36%
1,684 $8,000
Q3 2022

Nov 14, 2022

BUY
$2.43 - $4.51 $7,358 - $13,656
3,028 Added 114.09%
5,682 $20,000
Q2 2022

Aug 15, 2022

SELL
$1.87 - $5.0 $583 - $1,560
-312 Reduced 10.52%
2,654 $7,000
Q1 2022

May 16, 2022

SELL
$3.22 - $7.04 $9,682 - $21,169
-3,007 Reduced 50.34%
2,966 $13,000
Q4 2021

Feb 14, 2022

BUY
$6.23 - $7.6 $20,826 - $25,406
3,343 Added 127.11%
5,973 $41,000
Q3 2021

Nov 15, 2021

BUY
$7.09 - $10.71 $4,686 - $7,079
661 Added 33.57%
2,630 $20,000
Q2 2021

Aug 16, 2021

BUY
$7.96 - $10.07 $15,673 - $19,827
1,969 New
1,969 $20,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $245M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.